Corline Biomedical: €2.3m

Case

Corline, founded in 1991, develops, manufactures and markets heparin based solutions to improve kidney transplantation, cell therapies and applications in the evolving field of regenerative medicine. Coreline was granted € 2.3M from the SME Instrument HORIZON 2020, phase 2.

“This is absolutely fantastic for Corline! This grant is one of the highest allocations awarded to a Swedish life science company within SME Instrument and it will allow us to fully fund our entire clinical study on Renaparin®. Apart from the purely practical and economic implications, it is also a great recognition of our project. It is really encouraging that the European Commission has recognized the potential in our project. With this grant, we will be able to create a platform from which we can accelerate Corline’s growth in kidney transplantation and new indications. GAEU Consulting has been our advisor throughout the entire application process and wrote our grant application. The outstanding application scoring received is proof to the quality of their service. I highly recommend GAEU as Horizon 2020 advisors for Life Science companies.”  

- Henrik Nittmar, PhD CEO